Following the administration of diazepam to mothers in labour the clinical effects, changes in thermogenesis, and metabolism of the drug in the newborn were observed under carefully controlled conditions. A total maternal dose of 30 mg or less in the 15 hours before delivery had little effect on the infants' state. Larger doses, however, were accompanied by low Apgar scores at birth, apnoeic spells, hypotonia, reluctance to feed, and an impaired metabolic response to a cold stress. Measurement of plasma levels of diazepam and its active metabolite showed that both products were detectable in significant concentrations in some infants for up to eight days. We conclude that greater care should be taken in the use of this otherwise effective drug for the treatment of preeclampsia.
Introduction
In the past five years there has been an increasing use of diazepam in pregnancy and labour (Toulouse and Maffel 1965; Lean et al., 1968; de Alvarez and Zighelboim, 1969) . It is used in small doses as a tranquillizer (Flowers et al., 1969) and in much larger doses, often with hydrallazine, in the management of pre-eclampsia and eclampsia (Leinzinger 1969 (Leinzinger , 1970 Joyce and Kenyon, 1972) . Obstetric reports indicate successful control of blood pressure and prevention of convulsions, with little evidence of harm to the newborn (Leinzinger 1969 (Leinzinger , 1970  Joyce and Kenyon, 1972) . There have, however, been reports of hypotonia (Flowers et al., 1969; Rosanelli, 1970; Shannon et al., 1972) , low Apgar scores (Flowers et al., 1969) , and hypothermia (Owen et al., 1972) . Hyperbilirubinaemia was found to be due to the vehicle, sodium benzoate, with which the parenteral preparation was prepared (Schiff et al., 1971) .
We have observed that infants become hypothermic and manifest symptoms of central nervous system depression after the maternal administration of diazepam during labour. The rapid, active transplacental passage of diazepam is well documented (Scher et al., 1972; Shannon et al., 1972) . Its subsequent fate is less predictable, some studies showing that it is rapidly eliminated (Shannon et al., 1972) , while others have shown that it is detectable for long periods in the newborn circulation (Hailey et al., 1973 ).
An investigation was therefore undertaken (a) to assess the clinical status of infants after maternal diazepam, (b) to measure their metabolic response to a physiological cold stress, and (c) to measure maternal, cord, and neonatal plasma levels of diazepam and its metabolite desmethyldiazepam. The infants were placed in a metabolic chamber set at a temperature in the middle of their thermoneutral range (the environmental temperature range in which the metabolic rate is minimal) (Hey and Katz, 1970 (Randall et al., 1965) , and its persistence is therefore important. Fifthly, it was noted that a cross-ovel in degradation curves occurs at about two days ( fig. 3 ), indicating conversion of diazepam to desmethyldiazepam. Lastly, in five cases appreciable levels of diazepam were found in the infant even though the mother had been given the drug intramuscularly within three hours of delivery. Thus the absorption and transfer from mother to fetus is rapid, while the metabolism in the newborn baby may be greatly impaired. 
Conc lusion
Our data show that a total dose of 30 mg of diazepam in the 15 hours before delivery has little adverse effect on the infant. When a total dose in excess of 30 mg is given over the same period there is an increased incidence of low Apgar score. The infant may become apnoeic several hours after initiation of spontaneous respiration. Hypotonia, drowsiness, and reluctance to feed occur in a high proportion. All the cases studied had an impaired metabolic response to cold, which was more profound than in those infants who had not received diazepam.
In most cases the neonate is capable of metabolizing diazepam in small doses, but the drug and its active metabolite persist for at least a week in pharmacologically active concentrations after high doses to the mother. We wish to alert all obstetricians and those caring for neonates to the effects of maternal diazepam on the newborn infant. While we recognize the value of this drug in the treatment of pre-eclampsia and eclampsia we recommend caution in the doses used and careful observation of all infants born to these mothers for at least 36 hours after delivery. This is especially important when the infant is, by virtue of its size, maturity, or underlying disease, already susceptible to hypothermia, respiratory depression, or feeding difficulty.
